Decoy Therapeutics is trading 8.71% up now at $3.71, with the move appearing mainly linked to stronger biotechnology sentiment after Moderna and Merck reported successful Phase 3 personalized cancer-vaccine results.
- The Nasdaq Biotechnology Index climbed 5.2% in response.
- No new company-specific catalyst was identified for August 20, 2026.
- Recent second-quarter results, reported August 12, showed a $2.4 million loss and $228,000 revenue but do not explain today’s gain.